Related StoriesStudy raises chance for using ultrasound techniques to identify symptoms of preterm laborSonaCare Medical's Sonablate 450 concentrated ultrasound system receives FDA acceptance for ablation of prostate tissueClinical trial initiated to determine feasibility, protection of focused ultrasound to take care of depressionTotal net operating expenses were $0.5 million in the second quarter of 2011, compared to $10.2 million in the last year period. The reduce is due to the following: The Company recognized a one-time gain of $2.5 million on the U.S., a biotechnology organization with a pipeline of proprietary small molecule medications being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial outcomes for the half a year ended June 30, 2015 and updates on its drug development programs.S. Patent, Proposed Generic Name, and Next Advanced Clinical Research in Rheumatoid Arthritis & Psoriasis Through the second one fourth of 2015, Can-Fite reported positive data from additional analysis of its completed Phase II/III study that suggests CF101 as a potential systemic therapy for individuals with moderate-severe psoriasis, this despite the study not meeting its primary endpoint, as previously announced through the first one fourth of 2015.